Stockscreener 앱 받기
0.4946
3.06%
-0.0156
시간 외 거래:
.49
-0.0046
-0.93%
전일 마감가:
$0.5102
열려 있는:
$0.5198
하루 거래량:
3.80M
Relative Volume:
0.80
시가총액:
$115.32M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.6595
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-1.08%
1개월 성능:
+8.11%
6개월 성능:
-56.23%
1년 성능:
+24.55%
1일 변동 폭
$0.4862
$0.52
1주일 범위
$0.47
$0.52
52주 변동 폭
$0.3726
$3.179
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
명칭
Sangamo Therapeutics Inc
전화
(510) 970-6000
주소
501 CANAL BLVD., RICHMOND, CA
SGMO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.4946 | 122.70M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-13 | 업그레이드 | Truist | Hold → Buy |
| 2024-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-02-27 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2023-01-06 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-06-13 | 재개 | Wedbush | Neutral |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-01-07 | 재개 | Guggenheim | Neutral |
| 2021-01-06 | 개시 | Stifel | Hold |
| 2020-12-16 | 재개 | H.C. Wainwright | Buy |
| 2020-09-08 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | SunTrust | Buy |
| 2019-08-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-09 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2018-10-10 | 개시 | Guggenheim | Buy |
| 2018-06-20 | 개시 | BofA/Merrill | Buy |
| 2017-11-15 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2016-11-01 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2016-10-19 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-10-23 | 재개 | Jefferies | Buy |
| 2013-05-03 | 개시 | BioLogic Equity Research | Sell |
| 2011-02-23 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-07-29 | 재확인 | Wedbush | Outperform |
| 2009-10-19 | 개시 | Brean Murray | Sell |
| 2009-10-07 | 재확인 | Leerink Swann | Outperform |
| 2009-08-25 | 재확인 | JMP Securities | Mkt Outperform |
모두보기
Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스
What analysts say about Sangamo Therapeutics Inc. stockBreakout portfolio performance - jammulinksnews.com
Is Sangamo Therapeutics Inc. a good long term investmentExceptional trading results - PrintWeekIndia
What drives Sangamo Therapeutics Inc. stock priceTremendous wealth creation - jammulinksnews.com
Sangamo Therapeutics Inc. Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com
Why Sangamo Therapeutics Inc. stock is on top investor watchlistsAnalyst Grade Signals - beatles.ru
Hemoglobinopathies Market Set to Witness Significant Growth - openPR.com
Sangamo Therapeutics prices $23M securities offering - MSN
Why Sangamo Therapeutics Inc. stock attracts strong analyst attentionMinimized Risk Trading Plan - beatles.ru
H.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy Data - Insider Monkey
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sangamo Biosciences (SGMO), Pliant Therapeutics (PLRX) and Stevanato Group (STVN) - The Globe and Mail
Sangamo rises after trial data for Fabry disease therapy - MSN
Sangamo Therapeutics (SGMO) Receives Reiterated "Buy" Rating fro - GuruFocus
Transcat: HC Wainwright Reiterates Buy, Raises PT to $116 from $116. - AInvest
Sangamo's (SGMO) Promising Phase 1/2 Gene Therapy Results for Fa - GuruFocus
Sangamo reports positive results for Fabry disease gene therapy By Investing.com - Investing.com India
Sangamo Therapeutics shares fall 1.56% in after-hours after reporting positive topline results from Phase 1/2 STAAR study. - AInvest
Sangamo Biosciences Approves Amendments to Equity Plan - TipRanks
Treg Cell-Based Therapies Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Rapa Therapeutics, Orca Bio, Caladrius Biosciences, Sangamo Therapeut - The Globe and Mail
Certain Warrants of Sangamo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2025. - MarketScreener
Palmetto Grain Brokerage - Palmetto Grain Brokerage
H.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO) - MSN
Two Sigma Investments LP Acquires 698,296 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
10 Promising Biotech Stocks to Invest in (June 2025) - Securities.io
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering - Zenopa
Sangamo Therapeutics’ SWOT analysis: genomic medicine firm faces cash crunch - Investing.com UK
Lazard Asset Management LLC Takes Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
Captrust Financial Advisors Makes New $30,000 Investment in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World
StockNews.com Initiates Coverage on Sangamo Therapeutics (NASDAQ:SGMO) - Defense World
Barclays Issues Pessimistic Forecast for Sangamo Therapeutics (NASDAQ:SGMO) Stock Price - Defense World
Sangamo Biosciences’ Earnings Call: Progress Amid Challenges - TipRanks
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates - MSN
Barclays Updates Price Target for Sangamo Therapeutics (SGMO) | SGMO Stock News - GuruFocus
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock New - GuruFocus
Sangamo Biosciences Announces $23 Million Share Offering - TipRanks
Sangamo (SGMO) Price Target Reduced by Barclays | SGMO Stock News - GuruFocus
Sangamo Therapeutics (SGMO) Projects 2025 Operating Expenses Ami - GuruFocus
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo Finance
Sangamo Therapeutics Inc (SGMO) Q1 2025 Earnings Call Highlights - GuruFocus
Market Setbacks: Major Stocks Face Financial Hurdles - Finimize
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2025 Earnings Call Transcript - Insider Monkey
Sangamo Therapeutics (SGMO) Announces $23M Capital Raise - GuruFocus
Sangamo Therapeutics Inc (SGMO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):